Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization
International Journal of Clinical Oncology · 2026
DOI: 10.1007/s10147-026-03141-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Yukako Takehara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery and Transplantation, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatectomy, Neoplasm Recurrence, Local. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Local recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) or selective transarterial chemoembolization (sTACE) is relatively common. This study aimed to examine salvage hepatectomy as a treatment of such recurrences.
Methods
We retrospectively analyzed 382 patients who underwent up-front hepatectomy for treatment of HCC and 44 patients who underwent salvage hepatectomy for treatment of local recurrence after RFA or sTACE. Propensity score matching analysis was performed to account for group differences.
Results
Mean time between the initial treatment and salvage hepatectomy was 3.5 ± 3.0 years. At the time of salvage hepatectomy, macroscopic vessel invasion was present in 15 patients (34.1%) and mean tumor size was significantly larger (3.0 ± 1.7 cm vs. 2.4 ± 1.1 cm; p = 0.097). Propensity score matching resulted in 33 matched pairs. After matching, 5-year overall survival did not significantly differ between the salvage and up-front hepatectomy groups. Multivariate analysis in the salvage hepatectomy group showed that serum α-fetoprotein concentration > 100 ng/mL was the only independent predictor of overall and disease-free survival.
Conclusions
Salvage hepatectomy appears to be feasible for selected patients with local recurrence of HCC after RFA or sTACE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digestive Surgery and Transplantation, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan.
- Department of Digestive Surgery and Transplantation, Tokushima University Graduate School, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan. saito.yu.1001@tokushima-u.ac.jp.
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Takehara, Y., Saito, Y., Morine, Y., Yamada, S., Teraoku, H., Waki, Y., Ikemoto, T., & Shimada, M. (2026). Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03141-9
Vancouver
Takehara Y, Saito Y, Morine Y, Yamada S, Teraoku H, Waki Y, et al. Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03141-9
BibTeX
@article{Takehara2026,
author = {Takehara, Yukako and Saito, Yu and Morine, Yuji and Yamada, Shinichiro and Teraoku, Hiroki and Waki, Yuhei and Ikemoto, Tetsuya and Shimada, Mitsuo},
title = {Clinical impact of salvage hepatectomy for local recurrence of hepatocellular carcinoma after radiofrequency ablation or selective transarterial chemoembolization},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03141-9}
}
EUVIMED